Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases
Background: Patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations frequently develop brain metastases (BM). While KRAS G12C was once considered an undruggable target, the emergence of selective inhibitors has transformed it into a viable therapeutic option. However, effectiv...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2026-06-01
|
| Serier: | Journal of the National Cancer Center |
| Fag: | |
| Online adgang: | http://www.sciencedirect.com/science/article/pii/S266700542500122X |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
